Page last updated: 2024-12-06

myrmicacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Myrmicacin is a natural product that has been isolated from the venom of the ant *Myrmica rubra*. It is a potent inhibitor of acetylcholinesterase, an enzyme that plays a key role in the transmission of nerve impulses. Myrmicacin's structure is characterized by a unique bicyclic framework, which contributes to its biological activity. The compound has been studied for its potential as a pesticide and for its potential to treat neurological disorders. Its mode of action is thought to be related to its ability to bind to the active site of acetylcholinesterase, thereby preventing the enzyme from hydrolyzing acetylcholine. Myrmicacin has also been shown to exhibit antimicrobial activity. It is currently being investigated for its potential as a new therapeutic agent.'

myrmicacin: found in secretions of South American leaf-cutting ant; inhibitor for mitotic progression after metaphase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-hydroxydecanoic acid : A medium-chain fatty acid that is decanoic acid substituted at position 3 by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID26612
CHEMBL ID4448230
CHEBI ID132983
SCHEMBL ID155391
MeSH IDM0068392

Synonyms (46)

Synonym
LMFA01050153
3-hydroxy-decanoic acid
(+/-)-3-hydroxydecanoic acid, >=98%
myrmicacin
beta-hydroxydecanoic acid
14292-26-3
3-hydroxydecanoic acid
3-hydroxycapric acid
beta-hydroxycapric acid
CHEBI:132983
decanoic acid, 3-hydroxy-
A74EFF12-378B-4657-9726-F37DBE2A9013
FT-0669509
(+-)-3-hydroxydecanoic acid
5561-87-5
decanoic acid, 3-hydroxy-, (+-)-
unii-igh24u4amf
igh24u4amf ,
3-hda
33044-91-6
AKOS011680873
d,l-b-hydroxycapric acid
rac 3-hydroxydecanoic acid
(+/-)-3-hydroxy-decanoic acid
3-oh-c10
3-hydroxy capric acid
gtpl5848
decanoic acid,3-hydroxy-
SCHEMBL155391
(+/-)-3-hydroxydecanoic acid
3-hydroxydecanoic acid, (+/-)-
.beta.-hydroxydecanoic acid
(rs)-3-hydroxydecanoic acid
mfcd00133275
SS-4996
CHEMBL4448230 ,
HY-113057
CS-0059457
3-hydroxydecanoicacid
DTXSID40864486
Q15425812
A885072
bdbm50511005
SB47848
decanoic acid, 3-hydroxy-, (a+/-)-
PD052101

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In conclusion, the enhancement of PSP mucosal absorption by C10 and its derivatives is consistent with a pharmacokinetic model, assuming that the enhanced membrane permeability of PSP depends on the enhancer disappearance kinetics from the loop and its calcium ion sequestration capacity."( Pharmacokinetic analysis of the absorption enhancing action of decanoic acid and its derivatives in rats.
Higashi, Y; Kamata, A; Murakami, T; Takahashi, K; Yata, N; Yumoto, R, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antimitoticAny compound that inhibits cell division (mitosis).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3-hydroxy fatty acidAny fatty acid with a hydroxy functional group in the beta- or 3-position. beta-Hydroxy fatty acids accumulate during cardiac hypoxia, and can also be used as chemical markers of bacterial endotoxins.
medium-chain fatty acidAny fatty acid with a chain length of between C6 and C12.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)Ki3.31000.02361.29013.3100AID1546369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)EC50 (µMol)17.92500.08903.868710.0000AID1546364; AID1546366
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
biological_processG-protein coupled receptor 84Homo sapiens (human)
neuropeptide signaling pathwayG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
urotensin II receptor activityG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
specific granule membraneG-protein coupled receptor 84Homo sapiens (human)
tertiary granule membraneG-protein coupled receptor 84Homo sapiens (human)
receptor complexG-protein coupled receptor 84Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1546369Displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546370Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay relative to embelin2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546365Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546364Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546366Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1345177Human GPR84 (Class A Orphans)2013The Journal of biological chemistry, Apr-12, Volume: 288, Issue:15
Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.90)18.7374
1990's4 (13.79)18.2507
2000's11 (37.93)29.6817
2010's10 (34.48)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.50 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]